Literature DB >> 27229874

Percent slope analysis of dynamic magnetic resonance imaging for assessment of chemotherapy response of osteosarcoma or Ewing sarcoma: systematic review and meta-analysis.

Tadahiko Kubo1, Taisuke Furuta2, Muhammad P Johan2, Nobuo Adachi2, Mitsuo Ochi2.   

Abstract

OBJECTIVE: The objective of this systematic review is to provide an up-to-date and unprecedented summary of percent slope analysis of dynamic magnetic resonance imaging (MRI) for the preoperative evaluation of the chemotherapy response of osteosarcoma or Ewing sarcoma. MATERIALS AND
METHOD: Studies evaluating dynamic MRI for the preoperative evaluation of the chemotherapy response of osteosarcoma or Ewing sarcoma were systematically searched for in MEDLINE, EMBASE, and Web of Science. More than 60 % reduction of the slope of the time intensity curve derived from dynamic MRI was defined as a positive response. Pooled sensitivity and specificity for each study were calculated into 2 × 2 contingency tables. The DerSimonian-Laird random-effects method was used for determining the pooled diagnostic odds ratio and the area under curve (AUC) of the summary receiver operating characteristic (SROC) curve.
RESULTS: A total of six studies with 66 patients who fulfilled all of the inclusion criteria were considered for the meta-analysis. The pooled sensitivity and specificity were 0.73 (95 % CI, 0.54-0.88) and 0.83 (95 % CI, 0.67-0.94), respectively. A significant difference was found between the good and poor responders in the diagnostic odds ratio. The SROC curve showed that the AUC was 0.839, indicating diagnostic accuracy in estimating good therapy response.
CONCLUSION: The slope of the time intensity curve derived from dynamic MRI was useful for evaluating the histological response of patients to neoadjuvant chemotherapy in osteosarcoma or Ewing sarcoma.

Entities:  

Keywords:  Chemotherapy response; Dynamic magnetic resonance imaging; Ewing sarcoma; MRI; Meta-analysis; Osteosarcoma

Mesh:

Year:  2016        PMID: 27229874     DOI: 10.1007/s00256-016-2410-y

Source DB:  PubMed          Journal:  Skeletal Radiol        ISSN: 0364-2348            Impact factor:   2.199


  35 in total

1.  Assessment of osteosarcoma response to neoadjuvant chemotherapy: comparative usefulness of dynamic gadolinium-enhanced spin-echo magnetic resonance imaging and technetium-99m skeletal angioscintigraphy.

Authors:  P Ongolo-Zogo; P Thiesse; J Sau; C Desuzinges; J Y Blay; A Bonmartin; M Bochu; T Philip
Journal:  Eur Radiol       Date:  1999       Impact factor: 5.315

2.  Quantifying heterogeneity in a meta-analysis.

Authors:  Julian P T Higgins; Simon G Thompson
Journal:  Stat Med       Date:  2002-06-15       Impact factor: 2.373

3.  Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols.

Authors:  Stefan S Bielack; Beate Kempf-Bielack; Günter Delling; G Ulrich Exner; Silke Flege; Knut Helmke; Rainer Kotz; Mechthild Salzer-Kuntschik; Matthias Werner; Winfried Winkelmann; Andreas Zoubek; Heribert Jürgens; Kurt Winkler
Journal:  J Clin Oncol       Date:  2002-02-01       Impact factor: 44.544

4.  Dynamic MR imaging (DEMRI) of microcirculation in bone sarcoma.

Authors:  W E Reddick; J S Taylor; B D Fletcher
Journal:  J Magn Reson Imaging       Date:  1999-09       Impact factor: 4.813

5.  Osteosarcoma: preliminary results of in vivo assessment of tumor necrosis after chemotherapy with diffusion- and perfusion-weighted magnetic resonance imaging.

Authors:  Markus Uhl; Ulrich Saueressig; Miriam van Buiren; Udo Kontny; Charlotte Niemeyer; Gabriele Köhler; Kamil Ilyasov; Mathias Langer
Journal:  Invest Radiol       Date:  2006-08       Impact factor: 6.016

Review 6.  Bone and soft tissue tumors: the role of contrast agents for MR imaging.

Authors:  K L Verstraete; P Lang
Journal:  Eur J Radiol       Date:  2000-06       Impact factor: 3.528

7.  Primary osteogenic sarcoma: pathologic aspects in 20 patients after treatment with chemotherapy en bloc resection, and prosthetic bone replacement.

Authors:  A G Huvos; G Rosen; R C Marcove
Journal:  Arch Pathol Lab Med       Date:  1977-01       Impact factor: 5.534

8.  Evaluation of tumor blood flow in musculoskeletal lesions: dynamic contrast-enhanced MR imaging and its possibility when monitoring the response to preoperative chemotherapy-work in progress.

Authors:  Makoto Kajihara; Yoshifumi Sugawara; Kenshi Sakayama; Keiichi Kikuchi; Teruhito Mochizuki; Kenya Murase
Journal:  Radiat Med       Date:  2007-04-27

9.  Limitations of single slice dynamic contrast enhanced MR in pharmacokinetic modeling of bone sarcomas.

Authors:  Andoni P Toms; Lawrence M White; Rita Kandel; Robert R Bleakney; Michael Noseworthy; Shepstone Lee; Martin E Blackstein; Jay Wunder
Journal:  Acta Radiol       Date:  2009-06       Impact factor: 1.990

Review 10.  Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols.

Authors:  P S Tofts; G Brix; D L Buckley; J L Evelhoch; E Henderson; M V Knopp; H B Larsson; T Y Lee; N A Mayr; G J Parker; R E Port; J Taylor; R M Weisskoff
Journal:  J Magn Reson Imaging       Date:  1999-09       Impact factor: 4.813

View more
  14 in total

1.  Value of diffusion-weighted imaging for evaluating chemotherapy response in osteosarcoma: A meta-analysis.

Authors:  Tadahiko Kubo; Taisuke Furuta; Muhammad P Johan; Mitsuo Ochi; Nobuo Adachi
Journal:  Mol Clin Oncol       Date:  2017-05-29

2.  [18F]FDG PET/CT quantitative parameters for the prediction of histological response to induction chemotherapy and clinical outcome in patients with localised bone and soft-tissue Ewing sarcoma.

Authors:  Alessio Annovazzi; Virginia Ferraresi; Vincenzo Anelli; Renato Covello; Sabrina Vari; Carmine Zoccali; Roberto Biagini; Rosa Sciuto
Journal:  Eur Radiol       Date:  2021-03-13       Impact factor: 5.315

3.  T2-weighted MRI radiomics in high-grade intramedullary osteosarcoma: predictive accuracy in assessing histologic response to chemotherapy, overall survival, and disease-free survival.

Authors:  Lawrence M White; Angela Atinga; Ali M Naraghi; Katherine Lajkosz; Jay S Wunder; Peter Ferguson; Kim Tsoi; Anthony Griffin; Masoom Haider
Journal:  Skeletal Radiol       Date:  2022-07-01       Impact factor: 2.199

4.  Multiparametric MRI with diffusion-weighted imaging in predicting response to chemotherapy in cases of osteosarcoma and Ewing's sarcoma.

Authors:  Mahmoud Mohamed Saleh; Tamer Moustafa Abdelrahman; Youusef Madney; Ghada Mohamed; Ahmed Mohammed Shokry; Amr Farouk Moustafa
Journal:  Br J Radiol       Date:  2020-10-15       Impact factor: 3.039

5.  Prediction of Histologic Neoadjuvant Chemotherapy Response in Osteosarcoma Using Pretherapeutic MRI Radiomics.

Authors:  Amine Bouhamama; Benjamin Leporq; Wassef Khaled; Angéline Nemeth; Mehdi Brahmi; Julie Dufau; Perrine Marec-Bérard; Jean-Luc Drapé; François Gouin; Axelle Bertrand-Vasseur; Jean-Yves Blay; Olivier Beuf; Frank Pilleul
Journal:  Radiol Imaging Cancer       Date:  2022-09

Review 6.  Advances in the management of osteosarcoma.

Authors:  Stefan S Bielack; Stefanie Hecker-Nolting; Claudia Blattmann; Leo Kager
Journal:  F1000Res       Date:  2016-11-25

7.  Bufalin Inhibits Proliferation and Induces Apoptosis in Osteosarcoma Cells by Downregulating MicroRNA-221.

Authors:  Jianjun Zhang; Jingjing Sha; Yan Zhou; Kun Han; Yaling Wang; Yang Su; Xiuyi Yin; Haiyan Hu; Yang Yao
Journal:  Evid Based Complement Alternat Med       Date:  2016-12-15       Impact factor: 2.629

Review 8.  Current review of surgical management options for extremity bone sarcomas.

Authors:  Catalin Cirstoiu; Bogdan Cretu; Bogdan Serban; Zsombor Panti; Mihai Nica
Journal:  EFORT Open Rev       Date:  2019-05-10

9.  A correlation analysis between tumor imaging changes and p-AKT and HSP70 expression in tumor cells after osteosarcoma chemotherapy.

Authors:  Feng Ji; Ran Lv; Ting Zhao
Journal:  Oncol Lett       Date:  2017-09-20       Impact factor: 2.967

10.  A nomogram for predicting cancer-specific survival in patients with osteosarcoma as secondary malignancy.

Authors:  Yanqi He; Han Liu; Shuai Wang; Jianjun Zhang
Journal:  Sci Rep       Date:  2020-07-30       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.